Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180 ...

Everyone is getting squeezed by higher costs these days, including dental practice owners. A recent DrBicuspid.com survey found that practice owners are more worried about higher operating costs than ...

Morgan Stanley raised the firm’s price target on Walmart (WMT) to $89 from $82 and keeps an Overweight rating on the shares. The firm is expecting “modest upside” for Q3 results and Q4 implied ...

"The fourth quarter was a very strong finish to a transformational fiscal 2025 and indicative of the momentum in our Digital Banking business as we increasingly benefit from the operating leverage in ...

Given Wingstop's healthy pipeline of store expansion and technology-related investments such as smart kitchens and MyWingstop, long-term growth is intact. Near-term headwinds will lead to lower ...